ClinicalTrials.gg

Phobia, Social clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 368 studies for Phobia, Social across more than 10 countries. 59 are recruiting or about to start. 219 of them are mainly about Phobia, Social (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
246
Recruiting
46
Status unknown
23
Terminated
19
Not yet recruiting
13
Active, not recruiting
12

Phase

Phase 2
51
Phase 3
35
Phase 4
24
Phase 1
16
Early Phase 1
5

Where

United States
187
Canada
29
Sweden
25
Israel
14
Germany
13
United Kingdom
12

Who develops what

Add Phobia, Social to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 6 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Ono Pharmaceutical, Otsuka and Vanda Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
VQW-765☆ Track1 live phase-3 study: NCT07221578Vanda Pharmaceuticals

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.VQW-765 · Vanda Pharmaceuticals · Phase 3 main aimNCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder — primary endpoint: Subjective Units of Distress Scale (SUDS) · 500 enrolled
  • Jan 2027 est.NTX-1472 · Newleos Therapeutics, Inc. · Phase 2 main aimNCT07323784 A Study of NTX-1472 in Social Anxiety Disorder — primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs) · 100 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Phobia, Social studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SSRIs 1 open · Antipsychotics 10 · SNRIs 6 · Antiemetics 3

Coming up

21studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger. 14 (30%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 8 (17%) take healthy volunteers.

Recruiting studies that take each age, of 46
AgeWomenMen
106 (13%)6 (13%)
1838 (83%)38 (83%)
3034 (74%)34 (74%)
4033 (72%)33 (72%)
5031 (67%)31 (67%)
6526 (57%)26 (57%)
7514 (30%)14 (30%)
8511 (24%)11 (24%)

Across all 368 studies, recruiting or not: 77% stop at 75 or younger and 69% at 65; 26% take children; 1% are for women only and <1% for men only; 22% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Phobia, Social studies take

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 216 mo9–18 · 15 studies——
Interventional, no phase28 mo14–43 · 148 studies—28 mo15–44 · 142 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 368. Browse all 368 → or search them.